BCDA;BCDAW · Biocardia, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.24M | - | $936.0K | $1.37M | $1.53M | - | $931.0K | $800.0K | $1.24M | $2.38M |
| SG&A | $1.03M | - | $552.0K | $683.0K | $1.20M | - | $825.0K | $852.0K | $1.09M | $1.19M |
| Total Operating Expenses | $2.27M | - | $1.49M | $2.05M | $2.73M | - | $1.76M | $1.65M | $2.33M | $3.57M |
| D&A | $3.0K | - | $4.0K | $5.0K | $12.0K | - | $16.0K | $17.0K | $19.0K | $22.0K |
| Operating Income | ($2.27M) | - | ($1.49M) | ($2.05M) | ($2.73M) | - | ($1.76M) | ($1.65M) | ($2.27M) | ($3.51M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | $0 |
| Net Income | ($2.26M) | - | ($1.48M) | ($2.05M) | ($2.71M) | - | ($1.74M) | ($1.65M) | ($2.27M) | ($3.50M) |
| EPS - Basic | ($0.21) | - | ($0.24) | ($0.40) | ($0.59) | - | ($0.61) | ($0.88) | ($1.35) | ($2.55) |
| EPS - Diluted | ($0.59) | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $951.0K | $2.50M | $5.29M | $980.0K | $949.0K | $2.37M | $4.93M | $1.42M | $949.0K | $4.90M |
| Accounts Receivable | $20.0K | $20.0K | - | $10.0K | - | $0 | $10.0K | $10.0K | $58.0K | $153.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $820.0K | $641.0K | $1.08M | $1.23M | $818.0K | $385.0K | $569.0K | $1.45M | $1.03M | $861.0K |
| Current Assets | $1.14M | $2.73M | $5.37M | $1.20M | $1.17M | $2.62M | $5.06M | $1.57M | $1.26M | $5.29M |
| Total Assets | $1.71M | $3.41M | $6.15M | $2.09M | $2.17M | $3.72M | $6.27M | $2.89M | $2.68M | $7.13M |
| Current Liabilities | $2.78M | $2.43M | $3.31M | $3.64M | $3.23M | $2.32M | $2.84M | $4.07M | $4.07M | $4.00M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.78M | $2.52M | $3.52M | $3.98M | $3.69M | $2.89M | $3.51M | $4.85M | $4.95M | $5.23M |
| Stockholders' Equity | ($1.07M) | $895.0K | $2.63M | ($1.89M) | ($1.52M) | $837.0K | $2.75M | ($1.96M) | ($2.27M) | $1.90M |
| Retained Earnings | ($170.61M) | ($168.35M) | ($166.37M) | ($164.88M) | ($162.83M) | ($160.12M) | ($157.82M) | ($156.09M) | ($154.44M) | ($144.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.66M) | - | - | - | ($1.62M) | - | - | - | ($1.53M) | ($2.56M) |
| Investing Cash Flow | $0 | - | - | - | - | - | - | - | $0 | ($10.0K) |
| Financing Cash Flow | $117.0K | - | - | - | $196.0K | - | - | - | $1.38M | $64.0K |
| CapEx | $0 | - | - | - | - | - | - | - | $0 | $10.0K |
| Free Cash Flow | ($1.66M) | - | - | - | - | - | - | - | ($1.53M) | ($2.57M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.73 | - | - | - | - | - | - | - | 0.67 | 0.73 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -132.0% | - | -24.1% | -98.1% | -125.2% | - | -27.7% | -57.0% | -84.6% | -49.1% |
| Return on equity | 211.9% | - | -56.5% | 108.6% | 178.4% | - | -63.1% | 83.9% | 99.6% | -184.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.41 | 1.12 | 1.62 | 0.33 | 0.36 | 1.13 | 1.78 | 0.39 | 0.31 | 1.32 |
| Quick ratio | 0.41 | 1.12 | 1.62 | 0.33 | 0.36 | 1.13 | 1.78 | 0.39 | 0.31 | 1.32 |
| Cash ratio | 0.34 | 1.03 | 1.60 | 0.27 | 0.29 | 1.02 | 1.74 | 0.35 | 0.23 | 1.23 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.61 | 3.81 | 2.34 | -1.11 | -1.43 | 4.45 | 2.28 | -1.47 | -1.18 | 3.75 |
| Liabilities / Assets | 1.62 | 0.74 | 0.57 | 1.90 | 1.70 | 0.78 | 0.56 | 1.68 | 1.85 | 0.73 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 16.9% | - | 15.3% | -24.4% | -19.8% | - | 32.4% | 52.2% | 35.2% | -5.5% |
| Net income growth (YoY) | 16.7% | - | 14.6% | -24.5% | -19.6% | - | 32.5% | 51.9% | 35.2% | -5.3% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 40.5% | 12.6% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 29.9% | 6.9% | -4.6% | 3.8% | 33.2% | - | - | - | - | -74.2% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BioCardia against the 5 most active filers in the same SIC group.